Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.